1:00 Universal Lateral Flow Platform and Its Application to the Detection of IgG Antibodies to COVID-19
Marco A. Biamonte, Founder and Chief Executive Officer of DDTD
Our organization specializes in ultra-sensitive lateral flow assays. We have incorporated all our know-how into a “universal IgG assay”. This assay can be rapidly customized to detect an IgG response to any given antigen. In this presentation, we will show how the universal test can be adapted to COVID-19. The universal IgG assay is about to be commercialized so that research groups may use it for any antigen and disease of interest to them, without having to invest in a test developer or share confidential information about their antigen of choice.
1:20 The Critical Role of Antigens in COVID-19 Serological Test Development
Yinan Jiang, PhD, Product Development Manager, ACROBiosystems
This webinar will cover:
1:40 COVID-19 Serologies: Getting to Positive—or Feeling Confident about a Negative
Stephen A. Rawlings, MD, PhD, Clinical Fellow, Division of Infectious Diseases & Global Public Health, University of California
One critical piece of our response to SARS-CoV-2 and the re-opening of our global economies will be understanding who has been infected by SARS-CoV-2 and who is protected from re-infection. Traditionally, this is accomplished by checking for an immune response to the virus in someone suspected of being exposed. Serologies (antibodies) are the easiest way to check for that response and have served the medical community well for a number of other infectious agents. However, SARS-CoV-2 is different, and as we learn more about the immunology of the virus-host interaction, the implications for the global pandemic are huge.
Marco A. Biamonte, PhD
Founder and CEO, Drugs & Diagnostics for Tropical Diseases (DDTD)
Marco holds a PhD in organic chemistry from the University of Cambridge, UK, and performed post-doctoral studies at the Swiss Institute for Technology (ETH-Z). Marco worked as a medicinal chemist in the pharmaceutical industry for 14 years, mostly in oncology. He co-led up to 3 projects simultaneously in 3 different therapeutic areas and managed up to 12 chemists. He and his colleagues have had success in advancing 2 new drugs into clinical trials (BIIB-021 and BIIB-028, respectively in Phase II and Phase I). In 2011, motivated by a long-standing desire, Marco created DDTD.
Yinan Jiang, PhD
Product Development Manager, ACROBiosystems
Dr. Yinan Jiang is an expert on structural studies of protein complexes involved in virus-host interaction. His research focuses on elucidating the molecular mechanism of virus cell entry and viral immune evasion, including coronaviruses and influenza viruses. He has published research papers in high-profile journals such as Cell Research and Protein Cell. Dr. Jiang is currently working as Product Development Manager at ACROBiosystems. He is in charge of developing SARS-CoV-2 antigen proteins and kits for research use. Dr. Jiang received his bachelor’s degree in Biochemistry from Jilin University and completed his PhD studies in Structural Biology at Tsinghua University.
Stephen A. Rawlings, MD, PhD
Clinical Fellow, Division of Infectious Diseases & Global Public Health, University of California
Dr. Rawlings is a physician scientist interested in applying the latest laboratory techniques to the most pressing problems in infectious diseases. He received his MD and PhD from New York University focusing on HIV pathogenesis and latency. He completed internship and residency in Internal Medicine at University of California, San Diego where he is now in his last year of an Infectious Diseases fellowship. His research has continued to focus on HIV, with a focus on characterizing the distribution of HIV reservoirs throughout the body. When the novel coronavirus arrived in San Diego in February 2020, he began to collect samples from acutely infected and convalescent participants in a cohort that now includes more than 100 participants. These samples have been instrumental in testing and validating various platforms to detect the virus and understand the immune system’s response to infection.
This web search service is supported by Google Inc.